Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Biases and consistency of different assay methods for neurological biomarkers using Quanterix single-molecule-array technology: A secondary analysis method comparison study.

NeuroMarkers·2026
Same author

Simoa and MSD platforms show analytical discordance but comparable diagnostic performance for GFAP, NF-L, and T-tau in adolescent concussion.

Scientific reports·2026
Same author

Repetitive Mild Traumatic Brain Injury Causes Neuronal Damage in the APP/PS1 Mouse Model of Alzheimer's Disease Without an Enduring Impact on Amyloid Pathology, Sleep, or Epileptiform Activity.

Journal of neurotrauma·2026
Same author

Vascular contribution to cognitive impairment and dementia (VCID): proceedings of 2025 workshop of the Jackson Laboratory.

Mammalian genome : official journal of the International Mammalian Genome Society·2026
Same author

Pharmacological inhibition of O-GlcNAcase reduces pS129-α-synuclein positive aggregates in the substantia nigra of mThy1-hSNCA mice.

Journal of Parkinson's disease·2026
Same author

CAPS Plus: A Clinical Biomarker Scoring System to Predict Aβ Positivity and Facilitate Enrollment in Anti-Amyloid Clinical Trials.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Richard Camicioli1, Sandra E Black2, Michael J Borrie3,4

  • 1University of Alberta, Edmonton, AB, Canada.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

患有莱维体轻度认知障碍 (LB-MCI) 个体表现出高的tau-181和降低的粉样β (Aß) 水平,表明阿尔茨海默氏症共同病理. 这些血液生物标志物表明LB-MCI患者的病理负担较高.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经学 神经学
  • 生物化学 生化学
  • 神经科学是一个神经科学.

背景情况:

  • 轻度认知障碍 (MCI) 可能源于混合病理,使诊断复杂化.
  • 对于阿尔茨海默氏症病理和神经退行症的血液生物标志物在莱维体轻度认知障碍 (LB-MCI) 中未得到充分研究.
  • LB-MCI的特点是认知波动,帕金森症,幻觉和REM睡眠行为障碍 (RBD).

研究的目的:

  • 为了比较LB-MCI患者的血生物标志物水平与没有LB特征的MCI患者,健康对照 (HC) 和患有或没有MCI的帕金森病 (PD) 患者.
  • 通过使用血液标记物来调查LB-MCI中阿尔茨海默氏病共同病理的存在.

主要方法:

  • 在COMPASS-ND研究的参与者中,使用Simoa测量了粉样β (Aß) 42/40比率,tau-181,GFAP和NfL的血水平.
  • 根据既定标准,MCI参与者被归类为LB-MCI.
  • 进行了跨组的统计比较 (ANOVA,ANCOVA),根据年龄和性别进行了调整.

主要成果:

  • 与没有LB特征的HC,PD和MCI相比,LB-MCI组显示出明显较低的Aß 42/40比率和更高的tau-181.
  • 血GFAP和NfL水平在研究组之间没有显著差异.
  • 年龄和性别调整并没有改变这些初步发现.

结论:

  • LB-MCI患者表现出血生物标志物概况,表明同时存在阿尔茨海默氏症的共同病理.
  • 在LB-MCI中升高的tau-181表明潜在的更高的病理性大脑负担.
  • 需要进一步的研究来探索这些患者群体中的其他共同病理和突核病理.